Immunovia

Immunovia is a Lund-based diagnostics company focused on early detection of pancreatic cancer — one of the deadliest cancers with a 12% five-year survival rate. The company's PancreaSure blood test was commercially launched in the US in 2025, targeting 1.8 million high-risk individuals, and secured a reimbursement rate of $897 per test. Listed on Nasdaq Stockholm, Immunovia has approximately 13 employees and raised over SEK 140 million in 2025 to fund the US launch.